SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs > Bioelectronics Corp. (BIEL)

Financials out. 2Q/17 Rev $439.0K. $647.7K Loss

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Det_Robert_Thorne Member Profile
 
Followed By 141
Posts 8,001
Boards Moderated 5
Alias Born 01/24/11
160x600 placeholder
Det_Robert_Thorne   Tuesday, 08/15/17 04:39:24 PM
Re: Det_Robert_Thorne post# 108120
Post # of 116198 
Financials out. 2Q/17 Rev $439.0K. $647.7K Loss

BIEL's second quarter 2017 revenues of $439.0K were down 36% from 2Q/16 and the company showed a net operating loss of $483.4K. The net loss was $647.7K.

Gross margins fell to 27.1% in 2Q/17 from 67.9% in the prior quarter. Not sure why this happened, but the decline was similar to the drop from 3Q/16 to 4Q/16 (68% falling to 32%,) before rising back to 67.9%.

First half 2017 revenues were down 28% from 1H/16.

Only $17.2K in cash on balance sheet at end of the quarter. They will have been borrowing more cash in 3Q/17.

OS stands at 18.08B, up nearly 736M shares from the end of 1Q/17. The conversion of shares from notes issued at least six months ago was lower than I expected.

Revenues were lower than I thought they would be, considering the sales through Amazon and the BIEL's Actipatch website. (And yes, I undertand that BIEL now uses a distribution model).

BIEL borrowed another $744K by selling notes during the quarter, but spent all of it, as cash at the end of the quarter was only $17K.

Here's the report:

http://www.otcmarkets.com/financialReportViewer?symbol=BIEL&id=177529

"Soylent Green is people!!!"

Detective Robert Thorn: Telling uncomfortable truths since 2022

DRT is Charleton Heston's character in the 1973 movie, Soylent Green, set in the year 2022, and is not my real name

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist